Wall Street is Pounding the Table Over NVDA, RUN, LLY

Nvidia (NVDA) is experiencing significant analyst optimism ahead of earnings, with Citi projecting $56.8 billion in sales and multiple firms, including BofA and UBS, reiterating buy ratings and raising price targets, citing its strong positioning in AI and healthcare. Sunrun (RUN) received upgrades from Guggenheim, Jefferies, and BMO, driven by expectations of strong cash generation and potential capital returns by 2026. Eli Lilly (LLY) was upgraded by Leerink to outperform, anticipating catalysts from obesity treatment adoption and expanded Medicare/Medicaid access, further bolstered by a deal to cut Medicare/Medicaid GLP-1 treatment prices to $245 per month starting mid-2026.

Analysis

Nvidia (NVDA) is currently a focus of strong bullish analyst sentiment ahead of its upcoming earnings, with Citi projecting sales of $56.8 billion, surpassing the $54.6 billion analyst consensus. Both Citi and Bank of America have reiterated "Buy" ratings, with Citi raising its price target to $220 from $210, citing NVDA's strong positioning in healthcare and artificial intelligence. UBS further anticipates robust Q4 revenue guidance between $63 billion and $64 billion, setting a $235 price target.

Sunrun (RUN) has received multiple analyst upgrades, including Guggenheim's "Buy" rating with a $27 price target, driven by expectations of strong future cash generation. Jefferies also upgraded RUN to "Buy" with a $21 price target, anticipating robust cash flow execution by late this year and into 2026, potentially enabling capital returns. BMO's upgrade to "Market Perform" with a $19 price target similarly noted the potential for cash generation to support stock buybacks and dividends.

Eli Lilly (LLY) saw an "Outperform" upgrade from Leerink, based on expected catalysts from expanded obesity treatment adoption. A key driver is the company's deal to cut Medicare and Medicaid GLP-1 treatment prices to $245 per month starting mid-2026, which is projected to significantly expand market access by January 2027. This strategic pricing move aims to capitalize on anticipated growth in the obesity drug market.

Key Decisions for Investors

• Consider monitoring Nvidia's upcoming earnings report closely for confirmation of strong sales and Q4 guidance, given the significant analyst upgrades and bullish sentiment around its AI and healthcare positioning.
• Evaluate Sunrun for potential long-term positions, as multiple upgrades highlight an attractive entry point and strong prospects for capital returns through buybacks or dividends by 2026, contingent on cash generation.
• Assess Eli Lilly's strategic positioning in the obesity treatment market, particularly the impact of its Medicare/Medicaid pricing deal on future market share and revenue growth, following Leerink's "Outperform" upgrade.